Deliberazione
Autorizzazione allo studio clinico sperimentale, farmacologico, profit, denominato: “A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy” - Codice Protocollo CYPRESS STUDY
N° 142
del 21/03/2024
